Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

57 results

Filters applied: . Clear all
Page 1
Chronic thromboembolic disease among patients undergoing surgical pulmonary embolectomy for acute pulmonary embolism.
Zieliński D, Darocha S, Pietrasik A, Machowski M, Wróbel K, Kurzyna M, Pruszczyk P, Torbicki A, Biederman A. Zieliński D, et al. Among authors: torbicki a. J Cardiovasc Surg (Torino). 2024 Apr 18. doi: 10.23736/S0021-9509.24.12931-X. Online ahead of print. J Cardiovasc Surg (Torino). 2024. PMID: 38635283
The analysis comprised history, laboratory and imaging studies, early and long-term mortality, and postoperative complications. We determined predictive factors for chronic thromboembolic lesions and risk factors for death. ...
The analysis comprised history, laboratory and imaging studies, early and long-term mortality, and postoperative complications. We de …
The risk profile change in patients with severe chronic thromboembolic pulmonary hypertension treated with subcutaneous treprostinil.
Jansa P, Kopeć G, Torbicki A, Sadushi-Kolici R, Campean IA, Halank M, Simkova I, Steringer-Mascherbauer R, Salobir B, Klepetko W, Lindner J, Lang IM. Jansa P, et al. Among authors: torbicki a. Pulm Circ. 2023 Aug 21;13(3):e12274. doi: 10.1002/pul2.12274. eCollection 2023 Jul. Pulm Circ. 2023. PMID: 37609358 Free PMC article.
Chronic thromboembolic pulmonary hypertension (CTEPH) is successfully treatable with pulmonary endarterectomy (PEA), balloon pulmonary angioplasty, and medical therapy. Registry to Evaluate Early and Long-Term Pulmonary Arterial Hypertension Disease Management risk score ( …
Chronic thromboembolic pulmonary hypertension (CTEPH) is successfully treatable with pulmonary endarterectomy (PEA), balloon pulmonary angio …
Cancer-associated thrombosis: comparison of characteristics, treatment, and outcomes in oncologic and nononcologic patients followed by a pulmonary embolism response team.
Pietrasik A, Gąsecka A, Kurzyna P, Smyk JM, Wasilewski M, Wolański R, Wrona K, Darocha S, Zieliński D, Grabowski M, Torbicki A, Kurzyna M. Pietrasik A, et al. Among authors: torbicki a. Pol Arch Intern Med. 2023 Aug 30;133(7-8):16421. doi: 10.20452/pamw.16421. Epub 2023 Feb 3. Pol Arch Intern Med. 2023. PMID: 36734981 Free article.
Posthospital mortality up to 12 months after the PE diagnosis was 12.8% (10/78) in the OP and 4.2% (6/142) in the NOP group (P = 0.03). In a long-term survival analysis, cancer was associated with increased risk of mortality (hazard ratio, 2.44 [95% CI, 1.51-3.95]; P <0 …
Posthospital mortality up to 12 months after the PE diagnosis was 12.8% (10/78) in the OP and 4.2% (6/142) in the NOP group (P = 0.03). In a …
Acute pulmonary embolism with coexisting right heart thrombi in transit-surgical treatment of 20 consecutive patients.
Zieliński D, Zygier M, Dyk W, Wojdyga R, Wróbel K, Pirsztuk E, Szostakiewicz K, Szatkowski P, Darocha S, Kurzyna M, Ciurzyński M, Machowski M, Pruszczyk P, Torbicki A, Biederman A. Zieliński D, et al. Among authors: torbicki a. Eur J Cardiothorac Surg. 2023 Apr 3;63(4):ezad022. doi: 10.1093/ejcts/ezad022. Eur J Cardiothorac Surg. 2023. PMID: 36661312
The primary end point was hospital all-cause mortality; secondary end points were perioperative complications and long-term mortality. RESULTS: The analysis included 20 patients. There was no in-hospital death. ...The mean follow-up was 46 months (range 13-98). There was 1 …
The primary end point was hospital all-cause mortality; secondary end points were perioperative complications and long-term mortality …
Recovery of right ventricular function after intermediate-risk pulmonary embolism: results from the multicentre Pulmonary Embolism International Trial (PEITHO)-2.
Mavromanoli AC, Barco S, Ageno W, Bouvaist H, Brodmann M, Cuccia C, Couturaud F, Dellas C, Dimopoulos K, Duerschmied D, Empen K, Faggiano P, Ferrari E, Galiè N, Galvani M, Ghuysen A, Giannakoulas G, Huisman MV, Jiménez D, Kozak M, Lang IM, Meneveau N, Münzel T, Palazzini M, Petris AO, Piovaccari G, Salvi A, Schellong S, Schmidt KH, Verschuren F, Schmidtmann I, Toenges G, Klok FA, Konstantinides SV; PEITHO-2 Investigators. Mavromanoli AC, et al. Clin Res Cardiol. 2023 Oct;112(10):1372-1381. doi: 10.1007/s00392-022-02138-4. Epub 2022 Dec 21. Clin Res Cardiol. 2023. PMID: 36539534 Free PMC article. Clinical Trial.
Almost one in four patients, however, continued to have evidence of RV dysfunction over the long term....
Almost one in four patients, however, continued to have evidence of RV dysfunction over the long term....
Long-Term Safety, Tolerability and Survival in Patients with Pulmonary Arterial Hypertension Treated with Macitentan: Results from the SERAPHIN Open-Label Extension.
Souza R, Delcroix M, Galié N, Jansa P, Mehta S, Pulido T, Rubin L, Sastry BKS, Simonneau G, Sitbon O, Torbicki A, Boyanova N, Chamitava L, Stein C, Channick RN. Souza R, et al. Among authors: torbicki a. Adv Ther. 2022 Sep;39(9):4374-4390. doi: 10.1007/s12325-022-02199-x. Epub 2022 Jul 12. Adv Ther. 2022. PMID: 35819570 Free PMC article. Clinical Trial.
Its open-label extension study (SERAPHIN OL) further assessed long-term safety and tolerability of macitentan 10 mg in PAH patients. ...RESULTS: Of 742 patients randomised in SERAPHIN, 550 (74.1%) entered SERAPHIN OL (OL safety set); 242 patients were randomised to maciten …
Its open-label extension study (SERAPHIN OL) further assessed long-term safety and tolerability of macitentan 10 mg in PAH patients. …
Predictive value of chest HRCT for survival in idiopathic pulmonary arterial hypertension.
Kacprzak A, Burakowska B, Kurzyna M, Fijałkowska A, Florczyk M, Wieteska-Miłek M, Darocha S, Torbicki A, Szturmowicz M. Kacprzak A, et al. Among authors: torbicki a. Respir Res. 2021 Nov 17;22(1):293. doi: 10.1186/s12931-021-01893-8. Respir Res. 2021. PMID: 34789251 Free PMC article.
CGGO had a negative prognostic value for outcome in a 2-year perspective. This effect was not seen in the longer term, probably due to short survival of cGGO patients. CONCLUSIONS: Lung HRCT carries a significant independent prognostic information in IPAH, and in patients …
CGGO had a negative prognostic value for outcome in a 2-year perspective. This effect was not seen in the longer term, probably due t …
Balloon Pulmonary Angioplasty in Technically Operable and Technically Inoperable Chronic Thromboembolic Pulmonary Hypertension.
Darocha S, Araszkiewicz A, Kurzyna M, Banaszkiewicz M, Jankiewicz S, Dobosiewicz A, Sławek-Szmyt S, Janus M, Grymuza M, Pietrasik A, Mularek-Kubzdela T, Kędzierski P, Pietura R, Zieliński D, Biederman A, Lesiak M, Torbicki A. Darocha S, et al. Among authors: torbicki a. J Clin Med. 2021 Mar 3;10(5):1038. doi: 10.3390/jcm10051038. J Clin Med. 2021. PMID: 33802475 Free PMC article.
CONCLUSION: BPA may be beneficial in patients with p-CTEPH who cannot undergo pulmonary endarterectomy (PEA). Larger long-term studies are needed to better define the efficacy, safety, and optimal BPA procedural standards in this population....
CONCLUSION: BPA may be beneficial in patients with p-CTEPH who cannot undergo pulmonary endarterectomy (PEA). Larger long-term studie …
Assessment of electrocardiographic markers of acute and long-term hemodynamic improvement in patients with pulmonary hypertension.
Piłka M, Darocha S, Banaszkiewicz M, Wieteska-Miłek M, Mańczak M, Mańczak R, Kędzierski P, Florczyk M, Dobosiewicz A, Torbicki A, Kurzyna M. Piłka M, et al. Among authors: torbicki a. Ann Noninvasive Electrocardiol. 2020 Sep;25(5):e12758. doi: 10.1111/anec.12758. Epub 2020 Apr 26. Ann Noninvasive Electrocardiol. 2020. PMID: 32335975 Free PMC article.
We investigated the resolution of ECG markers of right ventricular hypertrophy (RVH) caused by acute and long-term hemodynamic improvement. METHODS: Twenty-nine (29) patients with chronic thromboembolic pulmonary hypertension (CTEPH) and seven patients with pulmonary arter …
We investigated the resolution of ECG markers of right ventricular hypertrophy (RVH) caused by acute and long-term hemodynamic improv …
Combination Therapy with Oral Treprostinil for Pulmonary Arterial Hypertension. A Double-Blind Placebo-controlled Clinical Trial.
White RJ, Jerjes-Sanchez C, Bohns Meyer GM, Pulido T, Sepulveda P, Wang KY, Grünig E, Hiremath S, Yu Z, Gangcheng Z, Yip WLJ, Zhang S, Khan A, Deng CQ, Grover R, Tapson VF; FREEDOM-EV Investigators. White RJ, et al. Am J Respir Crit Care Med. 2020 Mar 15;201(6):707-717. doi: 10.1164/rccm.201908-1640OC. Am J Respir Crit Care Med. 2020. PMID: 31765604 Free PMC article. Clinical Trial.
The primary endpoint was the time to first adjudicated clinical worsening event: death; hospitalization due to worsening PAH; initiation of inhaled or parenteral prostacyclin therapy; disease progression; or unsatisfactory long-term clinical response.Measurements and Main …
The primary endpoint was the time to first adjudicated clinical worsening event: death; hospitalization due to worsening PAH; initiation of …
57 results